A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Pazopanib (Primary) ; Vorinostat (Primary)
- Indications Cancer
- Focus Adverse reactions
- 14 Jun 2017 Status changed from active, no longer recruiting to completed.
- 27 Dec 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 07 Jun 2016 Results of a retrospective analysis of pazopanib from 4 phase I trials in patients with advanced sarcoma (NCT01339871, NCT01430572, NCT01454804, NCT01454804) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.